Earnings
It may not have always felt like it, but biotech has been in a bull market mode over the past two-and-a-half years, ever since the iShares Biotechnology Index (IBB) bottomed out at $80.01 on February 9, 2016.
After providing an update of its ongoing strategic review, New York-based Synergy Pharmaceuticals’ stock plunged more than 71 percent.
Shareholders’ Approval and Launch of Oxurion NV as new Company Name
Retrophin, Inc. today announced it will report third quarter 2018 financial results on Thursday, November 1, 2018 after the close of the U.S. financial markets.
TESARO, Inc. will announce third-quarter 2018 financial results on Thursday, November 1, 2018, after the close of the U.S. financial markets.
Plenty of biotech companies will be releasing their third-quarter financial reports next week. Let’s take a quick look at some of these companies and their top stories they reported through 3Q2018.
Customer receipts for the first quarter of FY2019 at $2.01 million, up 100% from the same period in FY2018 ($1.01 million)
Multiple biotech companies are scheduled to release their quarterly reports next week. BioSpace takes a quick look at some these companies and the announcements they have made through 3Q2018.
Buried deep in an announcement touting a 6 percent growth in net sales driven by strong revenue gains of Cosentyx, Swiss pharma giant Novartis reported it received a Complete Response Letter from the U.S. Food and Drug Administration for canakinumab as a potential treatment for cardiovascular risk reduction.
Early data from ongoing Phase 1/2 clinical trial with NOX-A12 shows promising immune responses in patients
PRESS RELEASES